Osteoporosis Therapeutics in Asia-Pacific Markets will be valued at $7.7 billion in 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies

ResearchMoz added Latest Research Report titled " Osteoporosis Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies " to it's Large Report database.

Osteoporosis, the most common metabolic bone disease, is characterized by low bone mass, microarchitectural deterioration of bone tissue, and a consequent increase in fracture risk. Osteoporosis is generally known as an asymptomatic disease, as there are no visible signs until a fracture occur. In most of the cases, fracture is the clinical outcome associated with osteoporosis, and it has a complex pathogenesis that involves trauma to the bone and increased skeletal fragility. Osteoporosis is a major global public health problem, associated with significant morbidity, mortality, and socioeconomic burden. An aging global population will result in an increased number of people living with the condition, thereby acting as a driver for revenue growth.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=784620

The osteoporosis market is undergoing a gradual transition from a focus on antiresorptive therapies to anabolic drug treatment. The market is set to be driven by recently launched products, and the approval of drugs that will supplement current market leaders and offer greater therapeutic options. The marketed products landscape comprises a wide range of treatment options, including bisphosphonates, SERMs, RANKL inhibitors, a dual-action non-bisphosphonate (strontium ranelate), calcitonins and PTH analogues. Nevertheless, significant unmet need remains for products that can improve bone formation, as well as effective antiresorptive therapies that offer increased compliance with few side effects.

Scope

• The osteoporosis Asia-Pacific market will be valued at $7.7 billion in 2022, growing from $4.5 billion in 2015 at a CAGR of 7.8%.
• Bisphosphonates and SERMs dominate the osteoporosis market. However, unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs of the osteoporosis market?
• How will immunotherapies such as Prolia contribute to growth?
• What effect will the patent expirations of currently branded therapies have on market value?

Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 10
2.1 Disease Introduction 11
2.2 Epidemiology 11
2.3 Symptoms 12
2.4 Etiology and Pathophysiology 14
2.4.1 Pathophysiology 14
2.5 Diagnosis 15
2.6 Disease Stages 17
2.7 Prognosis 20
2.8 Treatment Options 21
2.8.1 Treatment Algorithm 21
2.8.2 Pharmacological Treatments 22
2.8.3 Non-Pharmacological Treatments 24
2.8.4 Exercise 24
2.8.5 Dietary Interventions 24

3 Marketed Products 26
3.1 Overview 26
3.2 Bisphosphonates 26
3.2.1 Risedronate - Warner Chilcott 26
3.2.2 Alendronate - Merck & Co 28
3.2.3 Boniva (ibandronate) - Roche 29

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG